focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiopharma Cred. Regulatory News (BPCR)

Share Price Information for Biopharma Cred. (BPCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.878
Bid: 0.876
Ask: 0.88
Change: 0.00 (0.00%)
Spread: 0.004 (0.457%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.878
BPCR Live PriceLast checked at -
BioPharma Credit is an Investment Trust

To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transfer of Shares to the Premium Segment

5 Oct 2021 07:00

RNS Number : 9592N
BioPharma Credit PLC
05 October 2021
 

LEI: 213800AV55PYXAS7SY24

5 October 2021

BIOPHARMA CREDIT PLC

(THE "COMPANY")

 

TRANSFER OF ORDINARY SHARES TO THE PREMIUM SEGMENT OF THE LONDON STOCK EXCHANGE AND INTRODUCTION OF STERLING QUOTE

 

Further to its announcement on 30 September 2021, BioPharma Credit plc (the "Company" or "BioPharma Credit") is pleased to announce the admission of all of its ordinary shares (the "Ordinary Shares") to listing on the Official List of the Financial Conduct Authority and to trading on the Premium Segment of London Stock Exchange plc's Main Market ("Admission"). The application for Admission was approved by shareholder vote at the general meeting held on 30 September 2021.

Admission is expected to become effective at 8:00 a.m. today. The Company's existing ticker, ISIN and SEDOL will remain unchanged.

The Company has applied to introduce an additional market quote for the Ordinary Shares on the London Stock Exchange denominated in GBP (the "GBP Quote"), in connection with which the Company will introduce a new ticker and SEDOL with effect from 8:00 a.m. on 5 October 2021, as set out below. The GBP Quote will appear alongside the Company's existing USD market quote (the "USD Quote") and there will be no changes to the legal form or nature of the Company's shares nor to the reporting currency of the Company's financial statements or the NAV (which will remain in USD). 

USD Quote

GBP Quote

ISIN

GB00BDGKMY29

GB00BDGKMY29

SEDOL

BDGKMY2

BP2NZ40

Ticker

BPCR LN

BPCP LN

 

For Further Information

BioPharma Credit plc

Via Link Company Matters Limited

Company Secretary +44 (0)1392 477 509

 

J.P. Morgan Cazenove

William Simmonds / Harry Randall (Corporate Finance)

+44 (0)20 7742 4000

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

Biopharmacredit@buchanan.uk.com

 

 

About BioPharma Credit plc:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

Visit the BioPharma Credit website at http://bpcruk.com for more information.

Capitalised terms used but not defined in this announcement will have the same meaning as set out in the circular published by the Company on 10 September 2021 unless the context otherwise requires.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKQBKPBDDCKK
Date   Source Headline
13th May 202411:40 amRNSDirector/PDMR Shareholding
10th May 20243:11 pmRNSSTATEMENT RE COHERUS BIOSCIENCES, INC.
8th May 20243:52 pmRNSHolding(s) in Company
7th May 20246:15 pmRNSTransaction in Own Shares
3rd May 20246:15 pmRNSTransaction in Own Shares
2nd May 20246:15 pmRNSTransaction in Own Shares
2nd May 202412:18 pmRNSNEW INVESTMENT OF UP TO US$400 MILLION
1st May 202410:25 amRNSTotal Voting Rights
30th Apr 20246:15 pmRNSTransaction in Own Shares
29th Apr 20246:15 pmRNSTransaction in Own Shares
26th Apr 20246:15 pmRNSTransaction in Own Shares
24th Apr 20246:15 pmRNSTransaction in Own Shares
24th Apr 20247:00 amRNSNEW INVESTMENT OF UP TO US$100 MILLION
23rd Apr 20246:15 pmRNSTransaction in Own Shares
22nd Apr 20246:15 pmRNSTransaction in Own Shares
22nd Apr 20244:00 pmRNSNet Asset Value(s) and Monthly Factsheet
19th Apr 20246:15 pmRNSTransaction in Own Shares
18th Apr 20246:15 pmRNSTransaction in Own Shares
18th Apr 20246:00 pmRNSNotice of AGM
17th Apr 20246:15 pmRNSTransaction in Own Shares
16th Apr 20246:15 pmRNSTransaction in Own Shares
15th Apr 20246:15 pmRNSTransaction in Own Shares
12th Apr 20246:15 pmRNSTransaction in Own Shares
11th Apr 20246:15 pmRNSTransaction in Own Shares
10th Apr 20246:15 pmRNSTransaction in Own Shares
9th Apr 20246:15 pmRNSTransaction in Own Shares
8th Apr 20246:15 pmRNSTransaction in Own Shares
4th Apr 20246:15 pmRNSTransaction in Own Shares
3rd Apr 20246:15 pmRNSTransaction in Own Shares
2nd Apr 20246:15 pmRNSTransaction in Own Shares
27th Mar 20244:48 pmRNSDirector/PDMR Shareholding
27th Mar 20247:01 amRNSUPDATES TO THE DISCOUNT CONTROL MECHANISM
27th Mar 20247:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
25th Mar 202411:35 amRNSDirector/PDMR Shareholding
21st Mar 20244:05 pmRNSDividend Declaration
21st Mar 20244:00 pmRNSNet Asset Value(s)
15th Mar 20244:35 pmRNSUPDATE ON INVESTMENT
11th Mar 20244:00 pmRNSNet Asset Value(s) and Monthly Factsheet
1st Mar 20243:10 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSNotice of Full Year Results
26th Feb 20246:15 pmRNSTransaction in Own Shares
20th Feb 20246:15 pmRNSTransaction in Own Shares
19th Feb 20246:15 pmRNSTransaction in Own Shares
16th Feb 20246:15 pmRNSTransaction in Own Shares
13th Feb 20246:15 pmRNSTransaction in Own Shares
13th Feb 20247:00 amRNSSTATEMENT RE IMMUNOGEN, INC.
9th Feb 20246:15 pmRNSTransaction in Own Shares
8th Feb 20246:15 pmRNSTransaction in Own Shares
8th Feb 20247:00 amRNSDividend Declaration
7th Feb 20246:15 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.